Eledon Pharmaceuticals to present kidney transplant study data at congress

Wed, 20 May 2026 16:05:16 -0400

Eledon Pharmaceuticals Inc. (NASDAQ: ELDN) will present clinical data from its tegoprubart program for kidney transplant patients at the American Transplant Congress in Boston from June 20-24, 2026, according to a company statement.

The presentations will include updated results from the Phase 2 BESTOW clinical trial and new long-term data from the Phase 2 BESTOW extension study. Tegoprubart is an anti-CD40L antibody being studied for preventing rejection in kidney transplantation.

The company scheduled an oral presentation for June 22 at 12:03 p.m. ET titled "Phase 2 BESTOW Trial: Evaluating Tegoprubart's Safety and Efficacy in Preventing Kidney Transplant Rejection." Dr. Andrew Adams from

Eledon Pharmaceuticals to Present New Long-Term Data from Phase 2 BESTOW Trial of Tegoprubart for the Prevention of Rejection in Kidney Transplantation at American Transplant Congress

Wed, 20 May 2026 16:05:00 -0400

Conference call and webcast to discuss results to be held on June 22, 2026 at 8 a.m. ET

IRVINE, Calif., May 20, 2026 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (Nasdaq: ELDN) today announced that the Company will present new clinical data from its tegoprubart program in patients undergoing kidney transplantation in an oral and a poster presentation at the American Transplant Congress (ATC) taking place in Boston, MA from June 20-24, 2026. Results will include updated data from the Phase 2 BESTOW clinical trial and new long-term data from the Phase 2 BESTOW extension study.

Eledon Pharmaceuticals to Present New Long-Term Data from Phase 2 BESTOW Trial of Tegoprubart for the Prevention of Rejection in Kidney Transplantation at American Transplant Congress

Wed, 20 May 2026 16:05:00 -0400

Conference call and webcast to discuss results to be held on June 22, 2026 at 8 a.m. ET

Form SCHEDULE 13G/A Eledon Pharmaceuticals, Filed by: BIOTECHNOLOGY VALUE FUND L P

Fri, 15 May 2026 16:13:00 -0400

si-local-file:///var/storage/secattach/20260515/26505366.html

Form SCHEDULE 13G/A Eledon Pharmaceuticals, Filed by: BIOTECHNOLOGY VALUE FUND L P

Fri, 15 May 2026 16:13:00 -0400

si-local-file:///var/storage/secattach/20260515/26505366.html

Eledon Pharmaceuticals, Inc. (ELDN) Misses Q1 EPS by 15c

Wed, 13 May 2026 17:12:54 -0400

Eledon Pharmaceuticals, Inc. (NASDAQ: ELDN) reported Q1 EPS of ($0.33), $0.15 worse than the analyst estimate of ($0.18).

For earnings history and earnings-related data on Eledon Pharmaceuticals, Inc. (ELDN) click here.

Form 10-Q Eledon Pharmaceuticals, For: Mar 31

Wed, 13 May 2026 16:21:00 -0400

si-local-file:///var/storage/secattach/20260513/26486442.html

Form 10-Q Eledon Pharmaceuticals, For: Mar 31

Wed, 13 May 2026 16:21:00 -0400

si-local-file:///var/storage/secattach/20260513/26486442.html

Form 8-K Eledon Pharmaceuticals, For: May 13

Wed, 13 May 2026 16:15:00 -0400

si-local-file:///var/storage/secattach/20260513/26486230.html

Form 8-K Eledon Pharmaceuticals, For: May 13

Wed, 13 May 2026 16:15:00 -0400

si-local-file:///var/storage/secattach/20260513/26486230.html

Eledon Pharmaceuticals Reports First Quarter 2026 Financial Results and Recent Business Highlights

Wed, 13 May 2026 16:05:00 -0400

100% insulin independence achieved in 10 patients with type 1 diabetes treated with tegoprubart following islet transplantation in UChicago Medicine-led study

FDA Orphan Drug designation granted to tegoprubart for the prevention of allograft rejection in liver transplantation

Cash, cash equivalents and short-term investments totaled $111.1 million as of March 31, 2026

IRVINE, Calif., May 13, 2026 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (Nasdaq: ELDN) today reported its first quarter 2026 operating and financial results and provided recent business highlights.

“In the first quarter of 2026, we achieved significant

Eledon Pharmaceuticals Reports First Quarter 2026 Financial Results and Recent Business Highlights

Wed, 13 May 2026 16:05:00 -0400

100% insulin independence achieved in 10 patients with type 1 diabetes treated with tegoprubart following islet transplantation in UChicago Medicine-led study

FDA Orphan Drug designation granted to tegoprubart for the prevention of allograft rejection in liver transplantation

Cash, cash equivalents and short-term investments totaled $111.1 million as of March 31, 2026

“In the first quarter of 2026, we achieved significant

Form EFFECT Eledon Pharmaceuticals,

Tue, 12 May 2026 06:07:00 -0400

si-local-file:///var/storage/secattach/20260512/26472274.html

Form EFFECT Eledon Pharmaceuticals,

Tue, 12 May 2026 06:07:00 -0400

si-local-file:///var/storage/secattach/20260512/26472274.html

Eledon Pharmaceuticals (ELDN) files $500M mixed shelf

Fri, 01 May 2026 16:11:05 -0400

Eledon Pharmaceuticals (NASDAQ: ELDN) has filed $500,000,000 mixed shelf of:

Common Stock

Preferred Stock

Debt Securities

Warrants

Units

Eledon Pharmaceuticals (ELDN) files $500M mixed shelf

Fri, 01 May 2026 16:11:05 -0400

Eledon Pharmaceuticals (NASDAQ: ELDN) has filed $500,000,000 mixed shelf of:

Common Stock

Preferred Stock

Debt Securities

Warrants

Units

Form S-3 Eledon Pharmaceuticals,

Fri, 01 May 2026 16:09:00 -0400

si-local-file:///var/storage/secattach/20260501/26417684.html

Form S-3 Eledon Pharmaceuticals,

Fri, 01 May 2026 16:09:00 -0400

si-local-file:///var/storage/secattach/20260501/26417684.html

Form DEFA14A Eledon Pharmaceuticals,

Thu, 30 Apr 2026 17:06:00 -0400

si-local-file:///var/storage/secattach/20260430/26409960.html

Form DEFA14A Eledon Pharmaceuticals,

Thu, 30 Apr 2026 17:06:00 -0400

si-local-file:///var/storage/secattach/20260430/26409960.html

Form ARS Eledon Pharmaceuticals, For: Dec 31

Thu, 30 Apr 2026 17:04:00 -0400

si-local-file:///var/storage/secattach/20260430/26409919.html

Form ARS Eledon Pharmaceuticals, For: Dec 31

Thu, 30 Apr 2026 17:04:00 -0400

si-local-file:///var/storage/secattach/20260430/26409919.html

Form DEF 14A Eledon Pharmaceuticals, For: Jun 18

Thu, 30 Apr 2026 16:57:00 -0400

si-local-file:///var/storage/secattach/20260430/26409677.html

Form DEF 14A Eledon Pharmaceuticals, For: Jun 18

Thu, 30 Apr 2026 16:57:00 -0400

si-local-file:///var/storage/secattach/20260430/26409677.html

NewcelX Reports Financial Results for 2025 and Provides Shareholders with Update on Accelerated Development of Type 1 Diabetes Treatment in Collaboration with Eledon Pharmaceuticals in 2026

Thu, 30 Apr 2026 08:15:00 -0400

NewcelX and Eledon Pharmaceuticals are collaborating to advance one of the few scalable approaches to a potential functional cure in Type 1 Diabetes, NCEL-101, as the flagship program and key long-term value driver toward IND-enabling milestones

Substantially debt free, NewcelX recently closed a financing of up to approximately $3.4 million, including $1.35 million in cash and approximately $2 million of potential additional proceeds from the exercise of warrants, and has access to up to a $25 million Equity Line of Credit

Strengthened scientific leadership with appointment of Julien Boisdron, MD, Chief Medical Officer of a

StreetInsider.com News Articles

Eledon Pharmaceuticals to present kidney transplant study data at congress

Eledon Pharmaceuticals to Present New Long-Term Data from Phase 2 BESTOW Trial of Tegoprubart for the Prevention of Rejection in Kidney Transplantation at American Transplant Congress

Eledon Pharmaceuticals to Present New Long-Term Data from Phase 2 BESTOW Trial of Tegoprubart for the Prevention of Rejection in Kidney Transplantation at American Transplant Congress

Form SCHEDULE 13G/A Eledon Pharmaceuticals, Filed by: BIOTECHNOLOGY VALUE FUND L P

Form SCHEDULE 13G/A Eledon Pharmaceuticals, Filed by: BIOTECHNOLOGY VALUE FUND L P

Eledon Pharmaceuticals, Inc. (ELDN) Misses Q1 EPS by 15c

Form 10-Q Eledon Pharmaceuticals, For: Mar 31

Form 10-Q Eledon Pharmaceuticals, For: Mar 31

Form 8-K Eledon Pharmaceuticals, For: May 13

Form 8-K Eledon Pharmaceuticals, For: May 13

Eledon Pharmaceuticals Reports First Quarter 2026 Financial Results and Recent Business Highlights

Eledon Pharmaceuticals Reports First Quarter 2026 Financial Results and Recent Business Highlights

Form EFFECT Eledon Pharmaceuticals,

Form EFFECT Eledon Pharmaceuticals,

Eledon Pharmaceuticals (ELDN) files $500M mixed shelf

Eledon Pharmaceuticals (ELDN) files $500M mixed shelf

Form S-3 Eledon Pharmaceuticals,

Form S-3 Eledon Pharmaceuticals,

Form DEFA14A Eledon Pharmaceuticals,

Form DEFA14A Eledon Pharmaceuticals,

Form ARS Eledon Pharmaceuticals, For: Dec 31

Form ARS Eledon Pharmaceuticals, For: Dec 31

Form DEF 14A Eledon Pharmaceuticals, For: Jun 18

Form DEF 14A Eledon Pharmaceuticals, For: Jun 18

NewcelX Reports Financial Results for 2025 and Provides Shareholders with Update on Accelerated Development of Type 1 Diabetes Treatment in Collaboration with Eledon Pharmaceuticals in 2026